STOCK TITAN

[Form 4] NeuroOne Medical Technologies Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

NeuroOne Medical Technologies Corp. (NMTC) – insider Form 4 filed 07/02/2025

CEO, President and Director David A. Rosa reported one transaction dated 06/30/2025. The filing shows a disposition of 2,458 common shares at $0.678 per share under Transaction Code “F,” which, per SEC definitions, denotes shares withheld to cover taxes or exercise costs rather than an open-market sale. After the transaction, Rosa’s direct ownership stands at 1,158,831 shares.

The sale amounts to roughly 0.2 % of his reported direct holdings, indicating that the executive continues to hold a substantial equity stake and remains materially aligned with shareholders.

NeuroOne Medical Technologies Corp. (NMTC) – modulo insider Form 4 presentato il 02/07/2025

Il CEO, Presidente e Direttore David A. Rosa ha segnalato una transazione datata 30/06/2025. Il documento indica una cessione di 2.458 azioni ordinarie a $0,678 per azione con il Codice Transazione “F,” che, secondo la definizione della SEC, indica azioni trattenute per coprire tasse o costi di esercizio e non una vendita sul mercato aperto. Dopo questa operazione, la posizione diretta di Rosa è pari a 1.158.831 azioni.

La vendita rappresenta circa lo 0,2% delle sue partecipazioni dirette dichiarate, segnalando che l’amministratore continua a detenere una quota significativa e rimane sostanzialmente allineato con gli azionisti.

NeuroOne Medical Technologies Corp. (NMTC) – Formulario insider Form 4 presentado el 02/07/2025

El CEO, Presidente y Director David A. Rosa reportó una transacción fechada el 30/06/2025. El documento muestra una disposición de 2,458 acciones ordinarias a $0.678 por acción bajo el Código de Transacción “F,” que según la definición de la SEC, indica acciones retenidas para cubrir impuestos o costos de ejercicio, no una venta en el mercado abierto. Tras la transacción, la propiedad directa de Rosa es de 1,158,831 acciones.

La venta representa aproximadamente el 0.2% de sus participaciones directas reportadas, lo que indica que el ejecutivo sigue manteniendo una participación accionaria significativa y permanece alineado materialmente con los accionistas.

NeuroOne Medical Technologies Corp. (NMTC) – 내부자 Form 4, 2025년 7월 2일 제출

CEO 겸 사장 및 이사인 David A. Rosa가 2025년 6월 30일자로 한 건의 거래를 보고했습니다. 해당 신고서에는 2,458주 보통주 처분이 주당 $0.678에 거래 코드 “F”로 표시되어 있는데, SEC 정의에 따르면 이는 공개 시장 판매가 아닌 세금 또는 행사 비용 충당을 위한 주식 보류를 의미합니다. 거래 후 Rosa의 직접 소유 주식은 1,158,831주입니다.

이번 매각은 그의 직접 보유 주식의 약 0.2%에 해당하며, 경영진이 여전히 상당한 지분을 보유하고 있으며 주주들과 실질적으로 이해관계가 일치함을 나타냅니다.

NeuroOne Medical Technologies Corp. (NMTC) – formulaire insider Form 4 déposé le 02/07/2025

Le CEO, Président et Directeur David A. Rosa a déclaré une transaction datée du 30/06/2025. Le dépôt indique une cession de 2 458 actions ordinaires au prix de 0,678 $ par action sous le code de transaction « F », qui, selon la définition de la SEC, correspond à des actions retenues pour couvrir les impôts ou les coûts d'exercice plutôt qu'à une vente sur le marché ouvert. Après cette opération, la détention directe de Rosa s’élève à 1 158 831 actions.

Cette vente représente environ 0,2 % de ses participations directes déclarées, ce qui montre que le dirigeant conserve une participation significative et reste aligné de manière substantielle avec les actionnaires.

NeuroOne Medical Technologies Corp. (NMTC) – Insider-Formular 4 eingereicht am 02.07.2025

CEO, Präsident und Direktor David A. Rosa meldete eine Transaktion vom 30.06.2025. Die Meldung zeigt eine Veräußerung von 2.458 Stammaktien zu $0,678 pro Aktie unter dem Transaktionscode „F“, der laut SEC-Definitionen für zurückbehaltene Aktien zur Deckung von Steuern oder Ausübungskosten steht und keinen Verkauf am offenen Markt darstellt. Nach der Transaktion hält Rosa 1.158.831 Aktien direkt.

Der Verkauf entspricht etwa 0,2 % seiner gemeldeten Direktbeteiligung, was darauf hinweist, dass der Manager weiterhin eine bedeutende Beteiligung hält und materiell mit den Aktionären übereinstimmt.

Positive
  • CEO retains 1,158,831 shares post-transaction, indicating sustained alignment with shareholder interests and confidence in the company.
  • Transaction coded “F” denotes tax withholding rather than discretionary open-market selling, suggesting no negative signal about future prospects.
Negative
  • Insider share disposition, even if small (2,458 shares), can be perceived as a short-term negative signal by some investors.

Insights

TL;DR Small tax-related share disposition; executive still holds >1.15 M shares, signaling limited impact on ownership structure.

The Form 4 reveals a routine Code F transaction by CEO David A. Rosa, involving the surrender of 2,458 shares (≈0.2 % of his stake) at $0.678 to satisfy tax obligations. Because no open-market sale occurred and the post-transaction holding remains significant, the filing does not materially change insider alignment or float. The low dollar value (<$2 k) and minimal percentage reduction suggest a neutral financial impact.

TL;DR Routine Section 16 compliance; insider retains large position, maintaining governance alignment.

Code F dispositions are generally viewed as administrative rather than opportunistic. Rosa’s remaining 1.158 M shares reinforce commitment to the firm’s long-term strategy. From a governance lens, continued substantial ownership by the CEO is favorable, while the small withholding event raises no red flags. Overall, the action is not impactful to shareholder rights or control.

NeuroOne Medical Technologies Corp. (NMTC) – modulo insider Form 4 presentato il 02/07/2025

Il CEO, Presidente e Direttore David A. Rosa ha segnalato una transazione datata 30/06/2025. Il documento indica una cessione di 2.458 azioni ordinarie a $0,678 per azione con il Codice Transazione “F,” che, secondo la definizione della SEC, indica azioni trattenute per coprire tasse o costi di esercizio e non una vendita sul mercato aperto. Dopo questa operazione, la posizione diretta di Rosa è pari a 1.158.831 azioni.

La vendita rappresenta circa lo 0,2% delle sue partecipazioni dirette dichiarate, segnalando che l’amministratore continua a detenere una quota significativa e rimane sostanzialmente allineato con gli azionisti.

NeuroOne Medical Technologies Corp. (NMTC) – Formulario insider Form 4 presentado el 02/07/2025

El CEO, Presidente y Director David A. Rosa reportó una transacción fechada el 30/06/2025. El documento muestra una disposición de 2,458 acciones ordinarias a $0.678 por acción bajo el Código de Transacción “F,” que según la definición de la SEC, indica acciones retenidas para cubrir impuestos o costos de ejercicio, no una venta en el mercado abierto. Tras la transacción, la propiedad directa de Rosa es de 1,158,831 acciones.

La venta representa aproximadamente el 0.2% de sus participaciones directas reportadas, lo que indica que el ejecutivo sigue manteniendo una participación accionaria significativa y permanece alineado materialmente con los accionistas.

NeuroOne Medical Technologies Corp. (NMTC) – 내부자 Form 4, 2025년 7월 2일 제출

CEO 겸 사장 및 이사인 David A. Rosa가 2025년 6월 30일자로 한 건의 거래를 보고했습니다. 해당 신고서에는 2,458주 보통주 처분이 주당 $0.678에 거래 코드 “F”로 표시되어 있는데, SEC 정의에 따르면 이는 공개 시장 판매가 아닌 세금 또는 행사 비용 충당을 위한 주식 보류를 의미합니다. 거래 후 Rosa의 직접 소유 주식은 1,158,831주입니다.

이번 매각은 그의 직접 보유 주식의 약 0.2%에 해당하며, 경영진이 여전히 상당한 지분을 보유하고 있으며 주주들과 실질적으로 이해관계가 일치함을 나타냅니다.

NeuroOne Medical Technologies Corp. (NMTC) – formulaire insider Form 4 déposé le 02/07/2025

Le CEO, Président et Directeur David A. Rosa a déclaré une transaction datée du 30/06/2025. Le dépôt indique une cession de 2 458 actions ordinaires au prix de 0,678 $ par action sous le code de transaction « F », qui, selon la définition de la SEC, correspond à des actions retenues pour couvrir les impôts ou les coûts d'exercice plutôt qu'à une vente sur le marché ouvert. Après cette opération, la détention directe de Rosa s’élève à 1 158 831 actions.

Cette vente représente environ 0,2 % de ses participations directes déclarées, ce qui montre que le dirigeant conserve une participation significative et reste aligné de manière substantielle avec les actionnaires.

NeuroOne Medical Technologies Corp. (NMTC) – Insider-Formular 4 eingereicht am 02.07.2025

CEO, Präsident und Direktor David A. Rosa meldete eine Transaktion vom 30.06.2025. Die Meldung zeigt eine Veräußerung von 2.458 Stammaktien zu $0,678 pro Aktie unter dem Transaktionscode „F“, der laut SEC-Definitionen für zurückbehaltene Aktien zur Deckung von Steuern oder Ausübungskosten steht und keinen Verkauf am offenen Markt darstellt. Nach der Transaktion hält Rosa 1.158.831 Aktien direkt.

Der Verkauf entspricht etwa 0,2 % seiner gemeldeten Direktbeteiligung, was darauf hinweist, dass der Manager weiterhin eine bedeutende Beteiligung hält und materiell mit den Aktionären übereinstimmt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rosa David A

(Last) (First) (Middle)
7599 ANAGRAM DR.

(Street)
EDEN PRAIRIE MN 55344

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and President
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 F 2,458 D $0.678 1,158,831 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24, Power of Attorney, is attached
/s/ Emily Johns, by Power of Attorney 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NeuroOne (NMTC) shares did the CEO sell?

David A. Rosa disposed of 2,458 common shares on 06/30/2025.

What was the sale price of the NMTC shares?

The shares were valued at $0.678 each according to the Form 4 filing.

What does Transaction Code "F" mean in this NMTC Form 4?

Code F indicates shares withheld to pay taxes or exercise costs rather than an open-market sale.

How many NMTC shares does the CEO still own after the transaction?

After the disposition, Rosa directly owns 1,158,831 shares.

Does this insider sale significantly impact NMTC's ownership structure?

No. The 2,458-share disposition represents roughly 0.2 % of the CEO's stake and is considered immaterial.
Neuroone Med Technologies Corp

NASDAQ:NMTC

NMTC Rankings

NMTC Latest News

NMTC Latest SEC Filings

NMTC Stock Data

36.37M
43.49M
24%
16.68%
0.66%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE